Wall Street brokerages expect Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) to report sales of $21.79 million for the current quarter, Zacks reports. Five analysts have provided estimates for Fortress Biotech’s earnings, with estimates ranging from $19.30 million to $25.00 million. Fortress Biotech posted sales of $17.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.1%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Fortress Biotech will report full-year sales of $92.85 million for the current year, with estimates ranging from $76.60 million to $103.17 million. For the next financial year, analysts expect that the company will post sales of $144.70 million, with estimates ranging from $102.70 million to $244.84 million. Zacks’ sales averages are an average based on a survey of research firms that cover Fortress Biotech.
Fortress Biotech (NASDAQ:FBIO – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. During the same period last year, the business posted ($0.11) EPS.
NASDAQ:FBIO opened at $0.91 on Wednesday. The stock has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $2.00. Fortress Biotech has a 52-week low of $0.79 and a 52-week high of $4.49. The company has a market capitalization of $97.37 million, a PE ratio of -1.05 and a beta of 2.27. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 0.46.
Several hedge funds have recently made changes to their positions in FBIO. Renaissance Technologies LLC lifted its position in shares of Fortress Biotech by 1,005.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,101,300 shares of the biopharmaceutical company’s stock worth $1,498,000 after buying an additional 1,001,653 shares during the period. Acadian Asset Management LLC grew its stake in shares of Fortress Biotech by 169.1% during the first quarter. Acadian Asset Management LLC now owns 424,693 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 266,853 shares during the period. Morgan Stanley grew its stake in shares of Fortress Biotech by 768.2% during the second quarter. Morgan Stanley now owns 266,945 shares of the biopharmaceutical company’s stock worth $953,000 after purchasing an additional 236,198 shares during the period. GSA Capital Partners LLP acquired a new position in Fortress Biotech in the first quarter valued at about $277,000. Finally, Wells Fargo & Company MN grew its stake in Fortress Biotech by 293.5% in the fourth quarter. Wells Fargo & Company MN now owns 227,638 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 169,790 shares during the period. Institutional investors own 30.92% of the company’s stock.
About Fortress Biotech (Get Rating)
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.
- Get a free copy of the StockNews.com research report on Fortress Biotech (FBIO)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.